J Clin Endocrinol Metab

Does anastrozole impact height in children with CAH?

November 25, 2024

Anastrozole slowed bone maturation and improved height outcomes. Adjunct treatment with anastrozole in children with congenital adrenal hyperplasia (CAH) delays the rate of bone maturation and increases the predicted adult height over 6 years, with no significant increase in hydrocortisone doses, indicating its potential as an adjunct therapy for children with CAH and advanced bone age.

In this retrospective chart review, researchers analyzed Z-scores of bone age, predicted adult height and height corrected for bone age over an 8-year period in 60 CAH patients treated with anastrozole. Outcome changes were analyzed using weighted mixed-effects models, adjusting for sex, diagnosis, age at diagnosis, and average hydrocortisone dose before and during treatment with anastrozole.

Key findings

• Mean bone age Z-score: decreased from 4.2 to 2.0 and 1.3 at 4 and 6 years, respectively (p < 0.001).
• Predicted adult height Z-score: improved from -2.1 to -0.45 and 0.18 at 4 and 6 years, respectively (p < 0.001).
• Corrected height Z-scores: improved from -1.7 to -0.33 and 0.18 at 4 and 6 years, respectively (p < 0.001).
• No significant difference was found in the average total daily hydrocortisone dose used before or during treatment.

Source:

Al-Rayess H, et al. (2024, November 4). J Clin Endocrinol Metab. Anastrozole improves height outcomes in growing children with congenital adrenal hyperplasia due to 21-OHD. https://pubmed.ncbi.nlm.nih.gov/39492684/